Reference : NFKBIA Deletion in Glioblastomas.
Scientific journals : Article
Life sciences : Genetics & genetic processes
http://hdl.handle.net/2268/84334
NFKBIA Deletion in Glioblastomas.
English
Bredel, M. [> > > >]
Scholtens, D. M. [> > > >]
Yadav, A. K. [> > > >]
Alvarez, A. A. [> > > >]
Renfrow, J. J. [> > > >]
Chandler, J. P. [> > > >]
Yu, I. L. [> > > >]
Carro, M. S. [> > > >]
Dai, F. [> > > >]
Tagge, M. J. [> > > >]
Ferrarese, R. [> > > >]
Bredel, C. [> > > >]
Phillips, H. S. [> > > >]
Lukac, P. J. [> > > >]
Robe, Pierre mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine - Département des sciences biomédicales et précliniques >]
Weyerbrock, A. [> > > >]
Vogel, H. [> > > >]
Dubner, S. [> > > >]
Mobley, B. [> > > >]
He, X. [> > > >]
Scheck, A. C. [> > > >]
Sikic, B. I. [> > > >]
Aldape, K. D. [> > > >]
Chakravarti, A. [> > > >]
Harsh, G. R. [> > > >]
2011
New England Journal of Medicine [=NEJM]
Massachusetts Medical Society
Yes (verified by ORBi)
International
0028-4793
1533-4406
Waltham
MA
[en] Background Amplification and activating mutations of the epidermal growth factor receptor (EGFR) oncogene are molecular hallmarks of glioblastomas. We hypothesized that deletion of NFKBIA (encoding nuclear factor of kappa-light polypeptide gene enhancer in B-cells inhibitor-alpha), an inhibitor of the EGFR-signaling pathway, promotes tumorigenesis in glioblastomas that do not have alterations of EGFR. Methods We analyzed 790 human glioblastomas for deletions, mutations, or expression of NFKBIA and EGFR. We studied the tumor-suppressor activity of NFKBIA in tumor-cell culture. We compared the molecular results with the outcome of glioblastoma in 570 affected persons. Results NFKBIA is often deleted but not mutated in glioblastomas; most deletions occur in nonclassical subtypes of the disease. Deletion of NFKBIA and amplification of EGFR show a pattern of mutual exclusivity. Restoration of the expression of NFKBIA attenuated the malignant phenotype and increased the vulnerability to chemotherapy of cells cultured from tumors with NFKBIA deletion; it also reduced the viability of cells with EGFR amplification but not of cells with normal gene dosages of both NFKBIA and EGFR. Deletion and low expression of NFKBIA were associated with unfavorable outcomes. Patients who had tumors with NFKBIA deletion had outcomes that were similar to those in patients with tumors harboring EGFR amplification. These outcomes were poor as compared with the outcomes in patients with tumors that had normal gene dosages of NFKBIA and EGFR. A two-gene model that was based on expression of NFKBIA and O(6)-methylguanine DNA methyltransferase was strongly associated with the clinical course of the disease. Conclusions Deletion of NFKBIA has an effect that is similar to the effect of EGFR amplification in the pathogenesis of glioblastoma and is associated with comparatively short survival.
http://hdl.handle.net/2268/84334
10.1056/NEJMoa1006312

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
NFKBIA-14Robe.pdfPublisher postprint878.16 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.